Yuhong Shi1, Pedram Azimzadeh1, Sarada Jamingal1, Shannon Wentworth1, Janice Ferlitch1, James Koh2, Nariman Balenga1, John A Olson3. 1. Division of General and Oncologic Surgery, Department of Surgery, University of Maryland, School of Medicine, Baltimore, MD. 2. Department of Surgery, Duke University Medical Center, Durham, NC. 3. Division of General and Oncologic Surgery, Department of Surgery, University of Maryland, School of Medicine, Baltimore, MD. Electronic address: jaolson@som.umaryland.edu.
Abstract
BACKGROUND: Parathyroid tumors are mostly considered monoclonal neoplasms, the rationale for focused parathyroidectomy in primary hyperparathyroidism. We reported that flow sorting parathyroid tumor cells and methylation-sensitive polymerase chain reaction (me-PCR) of polymorphic human androgen receptor gene and phosphoglycerate kinase gene alleles in deoxyribonucleic acid reveals that ≤35% of parathyroid tumors are polyclonal. We sought to confirm these findings and assess for clinical relevance. METHODS: Parathyroid tumors from 286 female primary hyperparathyroidism patients were analyzed for clonal status. Tumor clonal status was compared with clinical variables and operative findings. Statistical analysis was performed and significance was established at P < .05. RESULTS: In the study, 176 (62%) patients were informative for human androgen receptor gene and/or phosphoglycerate kinase gene. Assignment of clonal status was made in 119 (68%) tumors, of which 64 (54%) were monoclonal and 55 (46%) were polyclonal. Comparison of tumor clonal status to clinical variables in patients with complete operative data (N = 82) showed that while clinical features were the same between tumor types, patients with polyclonal tumors more often had multiple gland disease (risk ratio 4.066, confidence interval, 1.016-16.26; P = .039) potentially missed at unilateral neck exploration. CONCLUSION: This work confirms that primary hyperparathyroidism is often the result of polyclonal tumors and that parathyroid tumor clonal status may be associated with multiple gland disease.
BACKGROUND:Parathyroid tumors are mostly considered monoclonal neoplasms, the rationale for focused parathyroidectomy in primary hyperparathyroidism. We reported that flow sorting parathyroid tumor cells and methylation-sensitive polymerase chain reaction (me-PCR) of polymorphic humanandrogen receptor gene and phosphoglycerate kinase gene alleles in deoxyribonucleic acid reveals that ≤35% of parathyroid tumors are polyclonal. We sought to confirm these findings and assess for clinical relevance. METHODS:Parathyroid tumors from 286 female primary hyperparathyroidismpatients were analyzed for clonal status. Tumor clonal status was compared with clinical variables and operative findings. Statistical analysis was performed and significance was established at P < .05. RESULTS: In the study, 176 (62%) patients were informative for humanandrogen receptor gene and/or phosphoglycerate kinase gene. Assignment of clonal status was made in 119 (68%) tumors, of which 64 (54%) were monoclonal and 55 (46%) were polyclonal. Comparison of tumor clonal status to clinical variables in patients with complete operative data (N = 82) showed that while clinical features were the same between tumor types, patients with polyclonal tumors more often had multiple gland disease (risk ratio 4.066, confidence interval, 1.016-16.26; P = .039) potentially missed at unilateral neck exploration. CONCLUSION: This work confirms that primary hyperparathyroidism is often the result of polyclonal tumors and that parathyroid tumor clonal status may be associated with multiple gland disease.
Authors: Kristin R Corrado; Simone Caixeta Andrade; Justin Bellizzi; Lilia D'Souza-Li; Andrew Arnold Journal: J Bone Miner Res Date: 2015-05-14 Impact factor: 6.741
Authors: E Friedman; K Sakaguchi; A E Bale; A Falchetti; E Streeten; M B Zimering; L S Weinstein; W O McBride; Y Nakamura; M L Brandi Journal: N Engl J Med Date: 1989-07-27 Impact factor: 91.245
Authors: Davide Prandi; Sylvan C Baca; Alessandro Romanel; Christopher E Barbieri; Juan-Miguel Mosquera; Jacqueline Fontugne; Himisha Beltran; Andrea Sboner; Levi A Garraway; Mark A Rubin; Francesca Demichelis Journal: Genome Biol Date: 2014-08-26 Impact factor: 13.583
Authors: Nariman Balenga; James Koh; Pedram Azimzadeh; Joyce Hogue; Mostafa Gabr; Joseph P Stains; John A Olson Journal: J Bone Miner Res Date: 2019-02-28 Impact factor: 6.741
Authors: Kristin E Goodsell; Jae P Ermer; Salman Zaheer; Rachel R Kelz; Douglas L Fraker; Heather Wachtel Journal: Am J Surg Date: 2021-01-19 Impact factor: 3.125